Ambitious growth targets set for Bayer Healthcare in 2014

15 March 2012

German drugs and crop sciences major Bayer (BAY: DE) sees good perspectives for its businesses in the medium term. Speaking at the Meet Management investor conference in Leverkusen yesterday (March 14), chief executive Marijn Dekkers told delegates that, in the life science areas - HealthCare and CropScience - Bayer anticipate further increases in sales and margins through 2014.

Sales of Bayer HealthCare are expected to reach approximately 20 billion euros ($26.24 billion) in 2014, while Bayer CropScience aims to raise sales to more than 8 billion euros. Bayer MaterialScience intends to further strengthen its leading position in the market. This subgroup plans to achieve volume gains in excess of the rate of global GDP growth. Targets are based on the most recent currency assumptions, including an exchange rate of $1.40 to the euro.

Optimism based on well-stocked pipeline

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK